Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corporate Responsibility With Teeth: GSK’s Developing Countries Unit

Executive Summary

Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.

You may also be interested in...



Janssen Forms Global Public Health Group To Deliver Its Medicines To Developing World

With the formation of the GPH group, Janssen joins GSK and Sanofi in putting corporate focus on developing and delivering affordable medicines for developing countries. But where GSK seeks to improve outcomes and turn a profit, for now Janssen’s first priority is human health.

Janssen Forms Global Public Health Group To Deliver Its Medicines To Developing World

With the formation of the GPH group, Janssen joins GSK and Sanofi in putting corporate focus on developing and delivering affordable medicines for developing countries. But where GSK seeks to improve outcomes and turn a profit, for now Janssen’s first priority is human health.

Vaccine Funding And Access Key To Pharma Success In Developing World

Vaccine consultant Jacqueline Keith in an interview described promising advances but also challenges to the funding, development, and delivery of vaccines to the neediest populations. The role of public/private partnerships at each stage of the vaccine value chain is critical to assuring win-win outcomes.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel